ProQR Therapeutics N.V Dossier
Qualitative Analysis
Business overview
ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to changing lives through the creation of transformative RNA therapies. Headquartered in Leiden, Netherlands, with a presence in Cambridge, Massachusetts, the company is pioneering a next-generation RNA base editing technology platform called Axiomer. Axiomer utilizes a cell's own editing machinery, specifically ADAR (Adenosine Deaminase Acting on RNA), to make precise single-nucleotide edits in RNA. This mechanism can reverse disease-causing mutations or modulate protein expression, potentially yielding a new class of medicines for both rare and prevalent diseases with high unmet medical needs. ProQR has transitioned its focus from traditional antisense oligonucleotides to this advanced ADAR-mediated RNA editing platform.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Exclusive corporate focus on the development of the proprietary Axiomer RNA base-editing technology platform, which recruits endogenous ADAR enzymes to make highly specific single-nucleotide edits in RNA.
Expected impact: Establishment of a new class of disease-modifying medicines across diverse therapeutic areas, including cholestatic, metabolic, and central nervous system diseases.
Integration of machine learning models and high-throughput screening to systematically design and optimize Axiomer editing oligonucleotides (EONs), supported by a newly formed AI Advisory Board.
Expected impact: Significant acceleration of drug discovery timelines, improved predictive performance for candidate selection, and scaled-up experimental data generation.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides ProQR with access to Ginkgo's 50+ instrument autonomous laboratory, Nebula, to generate high-throughput experimental data for AI-enabled drug discovery on the Axiomer platform.
Terms: Ginkgo Bioworks made a strategic equity investment in ProQR; specific financial terms were not publicly disclosed.
Focuses on the discovery, development, and commercialization of potential new RNA-editing medicines for genetic disorders in the liver and nervous system using the Axiomer platform.
Terms: ProQR achieved $4.5 million (~€3.9 million) in collaboration milestones during 2025, with potential for further milestone payments and data updates in 2026.
Supports the design, optimization, and clinical advancement of AX-2402, an editing oligonucleotide targeting MECP2 mutations to treat Rett syndrome.
Terms: Total funding of up to $9.2 million (including an initial $1 million grant in January 2024 and an additional $8.1 million expansion in late 2024).